4WF / Esperion Therap - LARVOL DELTA

"https://t.co/av87ie4WFk" (@ellyanaxx)

"https://t.co/av87ie4WFk" (@ellyanaxx)

"Second Sight Medical Products Inc. Announces Resumption of Its Early Feasibility Study of the Orion® Cortical Visual Prosthesis at UCLA https://t.co/jBEp4WFe4L" (@NewsFromBW)

Esperion Therapeutics: Annual Report 2013 (Esperion Therapeutics) - Anticipated patent expiry in US on Jul 12, 2030; Anticipated expiry of several issued US patents between 2021-2030 

Anticipated patent expiry • Dyslipidemia

The Incorporation of Oxidation Resistant ApoA1-4WF in Adeno-Associated Viral and Lentiviral Gene Vectors With Robust Cholesterol Efflux in vitro (AHA 2019) - "ApoA1-4WF transgene expression can be achieved with both AAV and lentiviral vector systems with retention of RCT under conditions of oxidative stress."

Preclinical • APOA1

"See a new #NSCLC activity via @PeerView, @benlevylungdoc, @hosseinborghaei, and Professor Tony Mok #ASCO19 #CME https://t.co/Mf4WFeoj0J" (@SpeakJen)

"The sugar substitute xylitol may help you lose weight, but it can be deadly for your dog, @US_FDA warns. https://t.co/Qdr4WFrFFY" (@AVMAvets)

Stent-based Gene Therapy of Restenosis with an Oxidation-resistant Apolipoprotein A1 Mutant (ATVB-PVD-GPM 2019) - "These findings suggest that 4WF mutated apoA1 is a promising candidate for stent based gene therapy of ISR in the HCD pig model."

"Bluebird Network Celebrates Missouri Network Alliance’s 20th Anniversary https://t.co/IcjT9a4WFo" (@NewsFromBW)